Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study - Wikidata - awgldk - TriplyDB

Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study

Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study

http://www.wikidata.org/entity/Q28294419

about

Immunotherapy for metastatic renal cell carcinoma A novel vaccine against Crimean-Congo Haemorrhagic Fever protects 100% of animals against lethal challenge in a mouse model Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities Therapeutic cancer vaccines: past, present, and future PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy The evolution of poxvirus vaccines Role of vaccine therapy for renal cell carcinoma in the era of targeted therapy Structural Insights into the Inhibition of Wnt Signaling by Cancer Antigen 5T4/Wnt-Activated Inhibitory Factor 1 Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?Immunotherapy for metastatic renal cell carcinoma.MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 viruses Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity.Novel immunotherapy in metastatic renal cell carcinoma.Immunotherapy for metastatic solid cancers Evaluation of MVA-5T4 as a novel immunotherapeutic vaccine in colorectal, renal and prostate cancer.A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years.Therapeutic cancer vaccines: are we there yet?An update on TroVax for the treatment of progressive castration-resistant prostate cancer Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy.Viral vector-based therapeutic cancer vaccines Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors.Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy Immune microenvironments in solid tumors: new targets for therapy.Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma Selection of recombinant MVA by rescue of the essential D4R gene.The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors Update on prostate cancer vaccines CD8+ T-cell clones specific for the 5T4 antigen target renal cell carcinoma tumor-initiating cells in a murine xenograft model Poxviral vectors for cancer immunotherapy A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication.A poxviral-based cancer vaccine the transcription factor twist inhibits primary tumor growth and metastases in a model of metastatic breast cancer and improves survival in a spontaneous prostate cancer model A single immunization with MVA expressing GnGc glycoproteins promotes epitope-specific CD8+-T cell activation and protects immune-competent mice against a lethal RVFV infection.Specific immunotherapy in renal cancer: a systematic review.Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects.Tumor biology and prognostic factors in renal cell carcinoma.TroVax(®) vaccine therapy for renal cell carcinoma.

P2860

Q24186688-B350DAEC-E33E-47F5-B8A8-70A4CC8CA747 Q24276422-DC250A65-7952-453A-9F6F-0DE15568E07B Q26769884-2E5E7990-EE53-4C52-8DCD-99A213ABFB13 Q26852437-40D84B21-296E-4F2D-A778-F870E5CF2723 Q26863283-8CA05798-F6E8-4455-B7F2-82F175C30FBD Q26865789-2C0A023C-9742-44A8-B394-7855CC01C89E Q26991589-4B901A7B-823E-49DA-BDDA-1086C7AE6E35 Q26995905-A3A7F7D0-175D-45A2-9188-6605E98CD88A Q27016032-47CD143F-4B72-4642-B806-D3ED955895D1 Q27681929-D40E68A7-524B-49B9-B894-B84CCAE68A4C Q28082461-96B36E95-BB71-44D3-9AEF-F23DA258D87F Q28301672-770886E6-8BC5-4D8F-9121-021FD4E1F3F8 Q30234458-D2128751-E487-464E-8187-BEC7E5DC3BB0 Q30358935-E5B56543-2EFB-48E6-B275-5C9DC6DA231D Q33679779-453A5018-D124-42E3-9454-6D3F6B6920C1 Q33863074-813C318A-D179-45DA-9CA1-2EA3E0C5F989 Q34219970-210FD6FF-74DA-49EC-BB67-C0B699C31063 Q34260594-E0B3EA20-F443-48F3-A333-6754816165D0 Q34464975-8F3E4E30-A271-47E7-A3C0-1A6CEEA622F4 Q34786691-EADCB7F9-9A1E-4535-B79E-10FEE682997C Q35050205-142D38B8-E2A4-48F0-910E-5A4C7274D31F Q35294382-AE1F4452-5CE6-4682-B96F-0A12ACAB381F Q35515080-49271640-4D31-4B15-A52C-5103C56BB41D Q35571248-A94D1FE5-A3F0-4279-8A62-600359037B03 Q35597086-A014ED1F-A768-48B8-9C52-6857703B9778 Q35634179-2C246C2F-9EF8-4B81-8D0C-FAAA5D2A5B14 Q35642044-9C6626CA-FE73-4E01-ABBE-41A06E81B818 Q35799377-38DD559B-4238-4696-8502-879D00E09953 Q35800430-CBA2324F-4881-4663-9458-A1DB49CF2CDA Q35975387-2F2F0118-AD2B-4C10-8374-96C7660586E1 Q36169608-0B73C14F-A7A9-4A16-BFEC-C3FA99ECAD70 Q36177214-E21D9A81-2BE8-4B40-95B6-1C32E8FF1922 Q36350388-6D2AD6AA-4150-4FD5-ADDD-524B33CBD22C Q36391900-D47E0271-9E90-4FAA-AA41-3124CF7B3A4E Q36414022-E539F249-1178-4412-B7B4-3B19D147CC66 Q37004283-0E4C9B3F-E596-4C3F-82A9-344C00F7D06B Q37632182-2DD6640A-9742-4C0A-BACF-BC4298AA78E8 Q37725613-0224E661-EB49-4828-A712-483C79F59B72 Q37846387-B1363B3F-17C6-4D07-859F-2BA5C09ADA78 Q37965748-1787A5FC-346A-4B8E-B205-6B67743ACDAE

P2860

Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study

http://www.wikidata.org/entity/Q28294419

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Vaccination of metastatic rena ...... ebo-controlled phase III study

@ast

Vaccination of metastatic rena ...... ebo-controlled phase III study

@en

Vaccination of metastatic rena ...... ebo-controlled phase III study

@nl

type

label

Vaccination of metastatic rena ...... ebo-controlled phase III study

@ast

Vaccination of metastatic rena ...... ebo-controlled phase III study

@en

Vaccination of metastatic rena ...... ebo-controlled phase III study

@nl

prefLabel

Vaccination of metastatic rena ...... ebo-controlled phase III study

@ast

Vaccination of metastatic rena ...... ebo-controlled phase III study

@en

Vaccination of metastatic rena ...... ebo-controlled phase III study

@nl

P1433

Q28294419-D491882A-6094-4AD7-A5E7-53BE98E934C9

P1476

Q28294419-DAF658CC-D303-4428-B7B4-6ED72B58F468

P2093

Q28294419-17CD4297-7124-476B-AC85-260404BA4E45

Q28294419-34BBAD0E-1D5C-4263-975A-9926D2AF78DA

Q28294419-4395A990-16E6-431E-8BC3-A5E7CC425255

Q28294419-652A4871-022F-4CD5-8A94-5B73393021DF

Q28294419-68CB67D5-8A8F-48A7-AAAA-4D4697EAD584

Q28294419-84AE6E6F-827B-4B2D-846F-32067C42E532

Q28294419-A3FA8E46-2653-4231-8BA6-0931171AD80E

Q28294419-BA03CBF9-4CE2-4536-96C3-84FDED161A98

Q28294419-D0DD4592-A999-40A0-9F0E-2A596C67823B

Q28294419-D6C1DB7B-A286-4664-9359-61D67FD84334

P304

Q28294419-2C39D279-FD62-4A77-82B4-3BA6635FD3A8

P31

Q28294419-2F4E6785-4254-4419-A4C3-1DBB95CE51FC

P356

Q28294419-1A505B90-CCBD-49CF-B709-82412AFC1A6E

P407

Q28294419-F1B50344-CA7E-4FBE-9910-C9F1BB64497D

P433

Q28294419-49D57C99-AD77-4487-B1EB-C6181FCE284B

P478

Q28294419-1EDA3667-7C9A-4B99-B90E-0D3DA49E8611

P577

Q28294419-C958899F-EB5A-4080-9D69-909305EC4C6A

P698

Q28294419-5F92523F-D7A9-4A95-B6E6-4BBC2DF650A5

P921

Q28294419-C1CB633F-3AA8-4D3F-9A28-DEA992F73492

P356

1078-0432.CCR-10-2082

P1433

Clinical Cancer Research

P1476

Vaccination of metastatic rena ...... ebo-controlled phase III study

@en

P2093

Cezary Szczylik

http://www.w3.org/2001/XMLSchema#string

Howard L Kaufman

http://www.w3.org/2001/XMLSchema#string

Jackie de Belin

http://www.w3.org/2001/XMLSchema#string

John A Thompson

http://www.w3.org/2001/XMLSchema#string

Madusha Goonewardena

http://www.w3.org/2001/XMLSchema#string

Mike McDonald

http://www.w3.org/2001/XMLSchema#string

Piotr Tomczak

http://www.w3.org/2001/XMLSchema#string

Richard Harrop

http://www.w3.org/2001/XMLSchema#string

Robert E Hawkins

http://www.w3.org/2001/XMLSchema#string

Robert J Amato

http://www.w3.org/2001/XMLSchema#string

P304

5539-47

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-10-2082

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2010-11-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20881001

http://www.w3.org/2001/XMLSchema#string

P921